FindTrial
Sign In

Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling

Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT04710056
Enrollment
Unknown
Registered
2021-01-14
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Lipodystrophy (GLD), Lipodystrophy, Monogenic Obesity (MOB)

Keywords

Leptin (LEP), Leptin Receptors (LEPR), Biallelic Loss of Function Variants of the LEP Gene

Brief summary

Provide Expanded Access to REGN4461 for patients with diseases associated with deficient leptin signaling.

Detailed description

Expanded Access requests are only being considered in response to Individual Patient and Intermediate-Size Population EAP Investigational New Drug (IND) applications. Availability will depend on location.

Interventions

DRUGREGN4461

To be provided by Regeneron

Sponsors

Regeneron Pharmaceuticals
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL

Inclusion criteria

Key Inclusion: N/A Key Exclusion: N/A

Contacts

CONTACTRequests for Expanded Access must be initiated by a treating physician. Physicians should contact
Managedaccessrequests@regeneron.com844-734-6643

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026